

**Chancroid Tables of Evidence 1990-2008**

<b>Ref</b>	<b>Location</b>	<b>Study type</b>	<b>Measure</b>	<b>Treatment Arms</b>	<b>Outcome</b>	<b>MIC A</b>	<b>MIC B</b>	<b>MIC C</b>	<b>Comment</b>
1#	Indiana	Experimental series with control	Resolution HIV VL	13 asymp HIV+	No change in CD4 or VL. Clinical course the same,				
2#		Editorial Commentary							
3	Nairobi	Randomized trial GUD	Resolution/ improvement f/u 7,14,21 d	<u>Azithro 1gm once</u> Erythro 500mg qid 7d	89% (A) versus 91% (E), 6/9 fx Hd (A), 4/4 fx (E)				Failure assoc with HIV, lack of circumcision
4#	India	Randomized trial Hd	Complete healing by 21d, improvement, failure	16 Cipro bid 3d 15 Erythro qid 7d 15 TMP/SMX bid 7d	15 cure 1 improvement 14 cure 1 improvement 8 cure 7 failure				
5	Nairobi	Randomized trial	Failure no change or worsening	<u>CTX 250mg once</u>	35% failures: 40% HIV+, 33% uncirc	CTX OK			
6	Nairobi	randomized		<u>Fleroxacin 200mg once</u> <u>Flerox 400mg once</u>	88% resp (Micro 92%) 78% resp (Micro 83%)				5% HIV- failed 27% HIV+ failed
7	Bangkok	randomized	f/u 4,7,14d	<u>Cipro 500mg once</u> <u>Cipro 1000mg once</u>	100% (Micro+) 93% (-) 98% (Micro+) 96% (-)				
8#	Nairobi	Randomized, placebo controlled Rx GUD, 56 Hd only etiology + 55 with mixed etiologies	Weekly f/u, reepith,cured, improved, not improved, worsened	<u>Cipro 500mg once</u> Erythro 500mg tid 7d placebo	f/u <90% 19% failures (all comers) 12% failures (all comers) Hd+ Cipro: 92% (4) Erythro: 91% (4)				Small % Hd+, many mixed infections, failure assoc with HIV+ if mixed, small numbers of failures

9	New Orleans	Susceptibility testing 100 clinical isolates				3 <sup>rd</sup> Gen Ceph 100% S	Azithro 100% S		B-lactamase producers
10	Bangkok /SF	Susceptibility testing 54 clinical isolates	PCN G CIP TCY OFX A/C CTX/CFX ERY AZY		A/C 46% ® CTX MIC 0.004 CFX MIC 0.25 TCY ® Ery MIC <4 AZY MIC <0.06 CIP MIC 0.008 OFX MIC 0.06 T/S x5 MIC >1				B lactamase producers 1 Thai isolate R cipro 41% isolates R TMP/SMX
11	Several NA cities	Randomized, 197 cases: 75 Hd+	1wk,2wk,3wk	<u>Azithro 1gm once</u> <u>CTX 250mg once</u>	By 3 <sup>rd</sup> visit: 100% Az healed 88% CTX healed				Healing associated with circ, few HIV+
12	Kigali, Rawanda	Open label, 108 pts All with Cx + Hd	7,14,21,28d Crossover not 'cured' by 7d	Cipro 500mg once <u>TMP/SMX 640mg</u> <u>once</u> Both + BPCN	76% (7d) 89% (14d) 53% (7d) 75% (14d)	Cipro 0.004- 0.06	T/S 50% MIC >4		71% HIV+ TMP/SMX R noted
13 #	Indiana	Experimental model of prophylaxis. HIV excluded.	Development of experimental chancroid after abc and then repeated exposure	Azithro 1 gm once  Cipro 500mg once	9/9 between 4 and 9 weeks 8/9 after 1 week and 1/9 after 2 weeks	Cipro 0.03	Azithro 0.012		All initially responded to therapy
14	Blantyre, Malawi	Out-pt clinic GUD Rx HIV+ 59% Hd 26% 70% f/u 778 pts	8-10d 'Delta D' (dm at start – dm at f/u/dm start)	BPCN+ Erythro 250mg tid 7d Erythro 500mg tid 7d T/S 960mg bid 7d Cipro 250mg qd 7d <u>Cipro 500mg x1</u>	<u>0 DD</u> <u>&lt;50%DD</u> 15% 3%  10% 3%  19% 10%  0% 10%				

					5% 3%				
15	Nairobi	Open Label 80♂ Cx+ Hd 28% HIV+	Weekly f/u Cure= reepth	Fleroxacin HIV+ 400mg qd 5d <u>Fleroxacin HIV-</u> <u>400mg once</u>	HIV+ 91 response (8 not healed) HIV- 95% response (7 not healed)				
16	UK	review			Refers to ref 8				
17	Atlanta	review							
19	Brazil	Open Label 60 (54 with f/u) Men 7 HIV +	Weekly f/u Cure=reepth at 21 <sup>st</sup> day	Azithro 1g Triamphenicol 5g	A: HIV + 0%; HIV- 86.3% T: HIV+66.6%; HIV – 92.0% HIV+ 28.5%; HIV – 89.3% ITT (73% and 89%)				Rescue treatment 7- 10 days or erythro. All clinical and bacteriologic failures

Reproduced from [16]:

Antimicrobial	Dose	Frequency	Duration	Route	Recommendation
erythromycin	500	Tid	7d	Po	WHO
Erythromycin	500	Qid	7d	Po	CDC,CEG
Azithromycin	1	Once		Po	CDC,CEG
Ceftriaxone	250	Once		Im	WHO,CDC,CEG
Ciprofloxacin	500	Once		Po	WHO,CEG
Ciprofloxacin	500	Bid	3d	Po	CDC,CEG
Spectinomycin	2	once		im	WHO

Cipro responses adapted from Schmid [17]:

Dose	ref	yr	Cured/treated (%)
500mg once**		Until 1995	236/265(89)
	8	1999	45/49(92) 'responded'
			<b>281/314(89)</b>
1g once		1989	42/42
500 bid one day		1988	43/44(98)
500mg bid 3d		1987	40/40(100)
	4	1998	16/16(100) cure or imp
			<b>56/56(100)</b>
250mg once 5d		1995	NS(100)

\*\* Reference 12 an outlier 40/55(73%) response.

## E. References

- 1) Jancowicz D et al. Experimental Infection with *H ducreyii* in Persons Who are Infected with HIV Does Not Cause Local or Augment Systemic Viral Replication **JID 2007**:195:1443.
- 2) Schmid G et al. Control of Bacterial Sexually Transmitted Diseases in the Developing World Is Possible. **CID 2005**:41:1313.
- 3) Tyndall et al. Single Dose Azithro for the Treatment of Chancroid: A Randomized Comparison with Erythro STD 1994:21:231
- 4) D'Souza P et al. A Comparative Study of the Therapeutic Response of Patient with Clinical Chancroid to Cipro, Erythro and Cotrimoxazole. **STD 1998**:25:293
- 5) Tyndall M et al. Ceftriaxone No Longer Predictably Cures Chancroid in Kenya. **JID 1993**:167:469.
- 6) McDonald K et al. Evaluation of Fleroxacin as Single Oral Dose Treatment of Culture Proven Chancroid in Nairobi Kenya. **AAC 1989**:33:612
- 7) Bohidatta L et al. Evaluation of 500mg and 1000mg Doses of Cipro for treatment of Chancroid. **AAC 1988**:723.
- 8) Malonza I et al. A Randomized Double Blind Placebo Controlled Trial of Single Dose Cipro versus Erythro of the Treatment of Chancroid in Nairobi Kenya. **JID 1999**:180:1886.
- 9) Aldridge K et al. Comparison of the In Vitro Activities of Various Parenteral and Oral Antimicrobial Agents Against Endemic *H. ducreyii*. **AAC 1993**:37:1986.
- 10) Knapp et al. In Vitro Susceptibilities of Isolates of *H ducreyii* from Thailand and the US to Currently Recommended and Newer Agents for the Treatment of Chancroid. **AAC 1993**:37:1552.
- 11) Martin D et al. Comparison of Azithro and Ceftriaxone for the Treatment of Chancroid. **CID 1995**:21:409.
- 12) Bogaerts J et al. Failure of Treatment for Chancroid in Rawanda is not related to HIV: In vitro Resistance of *H ducreyii* to TMP/SMX. [CID:1995:20:925](#).
- 13) Thornton et al. Prevention of Experimental *H ducreyii* Infection: A Randomized Controlled Clinical Trial. **JID 1998**:177:1608.

- 14) Behets et al. STD and HIV Control in Malawi: A Field Study of Genital Ulcer Disease. *JID* 1995;171:451.
- 15) Tyndall M et al. Fleroxacin in the Treatment of Chancroid: AN Open Study of Men Seropositive or Seronegative for HIV Type 1. *AJM* 1993;94:Suppl 3A: 855.
- 16) Lewis D. Chancroid: Clinical manifestations, diagnosis and management. **STI** 2002; 79:68.
- 17) Schmid G. Treatment of Chancroid, 1997. *CID* 1999;28 (Suppl 1):S14-20
- 18) Ronald A et al. Evaluation of New Anti-infective Drugs for the Treatment of Chancroid, *CID* 1992;15(suppl1) S108-14
- 19) Kemp M, Christensen, J, Lautenschlager, S, et al. European guidelines for the management of chancroid, 2011. *International J of STD & AIDS* 2011; 22-241-244
- 20) Belda Jr W, Di Chiacchio NG, Di chiacchio N, et al. A comparative study of single-dose treatment of chancroid using triamphenicol versus azithromycin. *The Brazilian Journal of Infectious Diseases* 2009; 13:218-220.
- 21) Mohammed Tahir T, Olumide Yetunde M. Chancroid and human immunodeficiency virus infection – a review. *International Journal of Dermatology* 2008; 47:1-8.
- 22) Peel T, Bhatti D, De Boer J et al. Chronic cutaneous ulcers secondary to *Haemophilus ducreyi* infection. *Medical Journal of Australia* 2010; 192:348-350.
- 23) Borges MC, Colares JKB, Lima DM, *Haemophilus ducreyi* detection by polymerase chain reaction in oesophageal lesions of HIV patients. *International Journal of STD & AIDS* 2009; 20:238-240.